東陽光(600673.SH):東陽光藥境內未上市股份申請全流通獲香港聯交所批准上市
格隆匯 8 月 19日丨東陽光(600673.SH)公佈,公司委託宜昌東陽光長江藥業股份有限公司(“東陽光藥”)辦理將公司所持有東陽光藥2.262億股內資股股份轉換為境外上市股份並在香港聯交所主板上市流通相關事宜。經向中國證監會提出H股全流通申請,東陽光藥於2020年6月2日收到了中國證監會下發的正式批覆文件,核准東陽光藥股東廣東東陽光科技控股股份有限公司所持2.262億股境內未上市股份轉為境外上市股份,批覆自核准之日起12個月有效。
收到上述核准批覆後,東陽光藥根據有關規定辦理本次股份轉換涉及的各項工作。經向香港聯交所上市委員會申請,東陽光藥於2020年8月18日獲得香港聯交所出具的上市批准,批准2.262億股H股上市及買賣。
目前,東陽光藥已就公司此次股份轉換涉及的2.262億股內資股向中國證券登記結算有限責任公司(“中國結算”)辦理了內資股註銷登記程序,並已代公司向中國結算申請設立了H股全流通專用賬户。上述股份轉換及上市事宜尚需辦理H股轉登記業務,履行香港聯交所、其他相關境內外監管部門要求的辦理股份登記、交易結算安排等有關程序。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.